The FDA has approved a breakthrough HIV drug from Gilead – Yeztugo, generic name lenacapavir (LEN) – that reduces the risk of transmitting the virus by 96 percent.
The drug is designed to be given as an injection by health care workers in clinics every six months.
To compare effectiveness, 2,180 participants in two highly successful trial studies used lenacapavir and 1,087 participants used Truvada, another drug from Gilead approved for prevention.
There were only two reported incidents of HIV in the lenacapavir test group versus nine in the Truvada group.
Read more at NBC News.
BREAKING: FDA approves a powerful HIV drug that nearly eliminated the spread of the virus in clinical trials.
[image or embed] — NBC News (@nbcnews.com) June 18, 2025 at 2:23 PM
Discover more from The Randy Report
Subscribe to get the latest posts sent to your email.